1388893-77-3

Upstream product

• 20826-94-2 ethyl (2-oxocyclopentyl)acetate 
• 1029689-54-0 ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate 
• 1388893-76-2 ethyl 2-[12-hydroxy-7-thia-9,11-diazatricyclo[6.4.0.0[2.6]]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-3-yl]acetate 

Downstream Products

• 1388893-87-5 tert-butyl N-(4-[[3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2.6]]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate 
• 1388893-89-7 tert-butyl N-(4-[[3-(2-ethoxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2.6]]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate 
• 1388893-88-6 4-[[3-(2-ethoxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yl]oxy]-N,N-dimethylcyclohexan-1-amine 
• 1388893-90-0 4-[[3-(2-methoxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yl]oxy]-N,N-dimethylcyclohexan-1-amine 
• 1388893-96-6 tert-butyl N-(4-[[(3S)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-7-thia-9,11-diazatricyclo[6.4.0.0[2.6]]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate 
• 1388893-97-7 tert-butyl N-(4-[[(3S)-3-(2-hydroxyethyl)-7-thia-9,11-diazatricyclo[6.4.0.0[2.6]]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate 
• 1388893-98-8 2-[(3S)-12-[(4-[[(tert-butoxy)carbonyl](methyl)amino]cyclohexyl)oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2.6]]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-3-yl]acetic acid 
• 1388894-00-5 tert-butyl N-(4-[[(3S)-3-[[(5-fluoropyridin-2-yl)carbamoyl]methyl]-7-thia-9,11-diazatricyclo[6.4.0.0(2,6)]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate 
• 1388893-99-9 2-[(3S)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2.6]]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-3-yl]-N-(5-fluoropyridin-2-yl)acetamide 
• 1388894-03-8 tert-butyl N-(4-[[(3S)-3-[(ethylcarbamoyl)methyl]-7-thia-9,11-diazatricyclo[6.4.0.0(2,6)]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yl]oxy]cyclohexyl)-N-methylcarbamate 
• 1388894-02-7 2-[(3S)-12-[[4-(dimethylamino)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-3-yl]N-ethylacetamide 
• 1388894-08-3 C₂₈H₄₆N₄O₃SSi 
• 1388894-06-1 C₂₂H₃₂N₄O₃S 
• 1388894-14-1 (3R)-3-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-12-[[4-(morpholin-4-yl)cyclohexyl]oxy]-7-thia-9,11-diazatricyclo[6.4.0.0[2.6]]dodeca-1⁽¹²⁾,2⁽⁶⁾,8,10-tetraene 

Relevant academic research and scientific papers

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

FLT3 INHIBITORS AND USES THEREOF

The present invention provides methods of using compounds of formula I: or compositions thereof for the inhibition of FLT3, and the treatment of FLT3-mediated disorders.

CDK8 INHIBITORS AND USES THEREOF

The present invention provides methods of using compounds of formula I: and compositions thereof for the inhibition of CDK8, and the treatment of CDK8-mediated disorders.

IRAK INHIBITORS AND USES THEREOF

The present invention provides thieno[2,3-d]pyrimidine derivative compounds, and pharmaceutical compositions thereof. The invention also includes methods inhibiting an IRAK protein kinase in a patient by administering the thieno[2,3-d]pyrimidine derivative compound. The invention also includes methods of treating an IRAK-mediated disorder, disease, or condition in a patient by administering the thieno[2,3-d]pyrimidine derivative compound.

IRAK INHIBITORS AND USES THEREOF

The present invention relates to compounds and methods useful for inhibiting one or more interleukin-l receptor-associated kinases ("IRAK"). In some embodiments, a provided compound inhibits IRAK-1 and IRAK-4. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.